Benzinga | May 5, 2021 07:36AM EDT

JMP Securities Maintains Market Outperform on Esperion Therapeutics, Lowers Price Target to $111

JMP Securities analyst Jason Butler maintains Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and lowers the price target from $191 to $111.